http://lookfordiagnosis.com
English
Spanish
Italian
Portuguese
French
Swedish
Astellas files NDA in US for Isavuconazole to treat zygomycosis
Astellas has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for the approval of isavuconazole to treat invasive aspergillosis and invasive mucormycosis (also known as zygomycosis), life-threatening fungal infections ...
Pharmaceutical Business Review - Thu, 10 Jul 2014 04:15

Astellas submits NDA for isavuconazole to treat deadly fungal infections
The Pharma Letter - Thu, 10 Jul 2014 04:03

Basilea's partner Astellas submits isavuconazole US NDA for the treatment of ...
MarketWatch - Wed, 09 Jul 2014 09:07

Astellas Seeks FDA Nod for Fungal Infection Treatment - Analyst Blog
NASDAQ - Thu, 10 Jul 2014 13:37

Astellas seeks isavuconazole approval from FDA for treatment of life ...
News-Medical.net - Wed, 09 Jul 2014 12:05

Astellas Isavuconazole Gets QIDP for Invasive Candidiasis
We note that isavuconazole also has QIDP designation in the U.S. for the treatment of invasive aspergillosis and mucormycosis (also known as zygomycosis). Additionally, isavuconazole has orphan drug status in the U.S. and Europe for the treatment of ...
Zacks.com - Thu, 17 Jul 2014 13:48

FDA Grants QIDP Designation to Astellas Candidiasis Treatment
Drug Discovery & Development - Wed, 16 Jul 2014 10:52

Basilea reports that isavuconazole received QIDP designation from US FDA for ...
Wall Street Journal - Wed, 16 Jul 2014 09:07

Basilea submits isavuconazole European Marketing Authorization Application ...
NASDAQ - Wed, 16 Jul 2014 22:15

Basilea reports that isavuconazole receives orphan drug designations in Europe ...
In the U.S., isavuconazole was granted FDA fast-track status and received QIDP and orphan drug designation for invasive aspergillosis and mucormycosis (zygomycosis). In the European Union, the drug received orphan drug designations for the treatment of ...
Wall Street Journal - Sun, 13 Jul 2014 22:15

Astellas Seeks FDA Nod for Fungal Infection Treatment
Astellas Pharma, Inc. (ALPMY) has filed a new drug application (NDA) with the FDA for isavuconazole for the treatment of invasive aspergillosis and mucormycosis (also known as zygomycosis). Astellas and partner Basilea Pharmaceutica Ltd. are jointly ...
Zacks.com - Thu, 10 Jul 2014 13:37

GNW-News: Basilea reicht europäischen Zulassungsantrag für Isavuconazol zur ...
Emerging invasive zygomycosis in a tertiary care center: epidemiology and associated risk factors. International Journal of Infectious Diseases 2010 (14S), e100-e103 7 J. Wingard. Zygomycosis: Epidemiology and treatment options. Proceedings 2006, (6) ...
Finanztreff - Wed, 16 Jul 2014 22:15

Astellas' Isavuconazole Gets QIDP for Invasive Candidiasis
Ad-Hoc-News (Pressemitteilung) - Thu, 17 Jul 2014 14:06

BBC America Renews Orphan Black, Broadchurch
... co-development partner Astellas Pharma Inc. submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis (zygomycosis).
Ad-Hoc-News (Pressemitteilung) - Wed, 09 Jul 2014 20:07



BRIEF-Basilea Pharmaceutica says isavuconazole receives orphan drug ...
... Basel, Switzerland, July 14, 2014 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reports today that the European Commission granted isavuconazole orphan drug designations for the treatment of invasive aspergillosis and mucormycosis (zygomycosis).
Ad-Hoc-News (Pressemitteilung) - Sun, 13 Jul 2014 23:22

Basileas Isavuconazol erhält in Europa Orphan-Drug-Status zur Behandlung ...
Finanztreff - Sun, 13 Jul 2014 22:33

Druva charts growth path for EMEA
... co-development partner Astellas Pharma Inc. submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis (zygomycosis).
Ad-Hoc-News (Pressemitteilung) - Wed, 09 Jul 2014 09:18


1  2  3  4  5  6  7  8    ->

Last update: April 2009
Statistics